Stay updated with breaking news from Danielle Le. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A new review paper was published in Oncotarget's Volume 14 on December 12, 2023, entitled, “Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in Brazil: Balancing efficacy, safety, and tolerability.”Credit: 2023 Xavier et al. A new review paper was published in
A new review paper was published in Oncotarget's Volume 14 on December 12, 2023, entitled, "Current perspectives on the management of refractory or relapsed classic Hodgkin lymphoma in Brazil: Balancing efficacy, safety, and tolerability."
MONTREAL, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has received pricing approval for Minjuvi® (tafasitamab) from the Drugs Market Regulation Chamber (“CMED”). As a result, Knight expects to launch Minjuvi® in Brazil in the second quarter of 2024. In July 2023, ANVISA (Agência Nacional de Vigilância Sanitária) granted Market Authoriz
(2023-10-16 | TSX:GUD) Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in Brazil
This open label clinical trial compares the effects of dexamethasone vs usual care on the number of days alive and free of mechanical ventilation at day 28 amon